Have your own idea? Try our Stock Screener
Hong Kong (HSI) Life Sciences Industry Analysis
UpdatedAug 31, 2025
DataAggregated Company Financials
Companies11
- 7D-0.9%
- 3M43.9%
- 1Y119.9%
- YTD82.8%
The Life Sciences industry has been flat over the last week, but Genscript Biotech has lost 7.1%. The past year has been better, since the industry has gained 120% in that time. Looking forward, earnings are forecast to grow by 33% annually.
Industry Valuation and Performance
Has the Hong Kong Life Sciences Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sun, 31 Aug 2025 | HK$303.7b | HK$41.9b | HK$6.0b | 57.2x | 50.6x | 7.3x |
| Tue, 29 Jul 2025 | HK$285.7b | HK$37.2b | HK$2.7b | 60.5x | 104.2x | 7.7x |
| Thu, 26 Jun 2025 | HK$218.5b | HK$36.3b | HK$2.6b | 28.5x | 83.6x | 6x |
| Sat, 24 May 2025 | HK$194.9b | HK$36.2b | HK$2.6b | 26.5x | 74.9x | 5.4x |
| Mon, 21 Apr 2025 | HK$169.6b | HK$35.4b | HK$2.5b | 24x | 67.1x | 4.8x |
| Wed, 19 Mar 2025 | HK$228.4b | HK$32.7b | -HK$202,460,494.17 | 49.1x | -1128x | 7x |
| Fri, 14 Feb 2025 | HK$171.6b | HK$35.8b | -HK$1,060,919,669.78 | 52.7x | -161.7x | 4.8x |
| Sun, 12 Jan 2025 | HK$151.3b | HK$35.6b | -HK$1,062,130,458.29 | 62.6x | -142.5x | 4.2x |
| Tue, 10 Dec 2024 | HK$165.1b | HK$35.8b | -HK$1,057,872,578.99 | 59.3x | -156.1x | 4.6x |
| Thu, 07 Nov 2024 | HK$156.8b | HK$35.5b | -HK$665,828,377.13 | 40.1x | -235.5x | 4.4x |
| Sat, 05 Oct 2024 | HK$195.3b | HK$35.9b | -HK$652,704,448.85 | 44.4x | -299.2x | 5.4x |
| Mon, 02 Sep 2024 | HK$127.6b | HK$35.9b | -HK$659,504,477.72 | 25.6x | -193.4x | 3.6x |
| Wed, 31 Jul 2024 | HK$90.2b | HK$33.5b | HK$3.1b | 17x | 29.2x | 2.7x |
| Fri, 28 Jun 2024 | HK$90.2b | HK$33.4b | HK$3.1b | 19.6x | 29.4x | 2.7x |
| Sun, 26 May 2024 | HK$96.4b | HK$33.5b | HK$3.1b | 29.5x | 31.2x | 2.9x |
| Tue, 23 Apr 2024 | HK$99.4b | HK$33.6b | HK$3.1b | 31.3x | 32.1x | 3x |
| Thu, 21 Mar 2024 | HK$116.5b | HK$33.3b | HK$3.7b | 49.9x | 31.7x | 3.5x |
| Sat, 17 Feb 2024 | HK$125.1b | HK$32.5b | HK$3.0b | 46.9x | 41.4x | 3.8x |
| Mon, 15 Jan 2024 | HK$206.0b | HK$32.4b | HK$3.0b | 85.9x | 68.8x | 6.4x |
| Wed, 13 Dec 2023 | HK$205.8b | HK$32.3b | HK$3.0b | 82.5x | 69x | 6.4x |
| Fri, 10 Nov 2023 | HK$272.7b | HK$30.1b | HK$2.7b | 48.2x | 101.9x | 9.1x |
| Sun, 08 Oct 2023 | HK$236.4b | HK$30.2b | HK$2.7b | 41.7x | 88.3x | 7.8x |
| Tue, 05 Sep 2023 | HK$239.0b | HK$30.3b | HK$2.7b | 42.7x | 88.7x | 7.9x |
| Thu, 03 Aug 2023 | HK$236.3b | HK$28.4b | HK$2.7b | 22.7x | 86.5x | 8.3x |
| Sat, 01 Jul 2023 | HK$204.3b | HK$28.3b | HK$2.7b | 20.2x | 75.9x | 7.2x |
| Mon, 29 May 2023 | HK$229.1b | HK$28.9b | HK$2.8b | 22.6x | 81.4x | 7.9x |
| Wed, 26 Apr 2023 | HK$246.9b | HK$29.4b | HK$2.9b | 24.7x | 84.7x | 8.4x |
| Fri, 24 Mar 2023 | HK$264.1b | HK$26.6b | HK$2.1b | 23.6x | 125.3x | 9.9x |
| Sun, 19 Feb 2023 | HK$296.3b | HK$26.4b | HK$2.1b | 25.2x | 143x | 11.2x |
| Tue, 17 Jan 2023 | HK$383.1b | HK$26.7b | HK$2.2b | 31.8x | 176.9x | 14.3x |
| Thu, 15 Dec 2022 | HK$273.3b | HK$25.9b | HK$2.0b | 28.4x | 136.8x | 10.5x |
| Sat, 12 Nov 2022 | HK$270.9b | HK$25.5b | HK$1.8b | 23.2x | 147x | 10.6x |
| Mon, 10 Oct 2022 | HK$247.6b | HK$25.7b | HK$1.9b | 20.2x | 129.9x | 9.6x |
| Wed, 07 Sep 2022 | HK$332.2b | HK$26.2b | HK$2.0b | 25.2x | 163.6x | 12.7x |
Price to Earnings Ratio
163.6x
Current Industry PE
- Investors are optimistic on the Hong Kong Life Sciences industry, and appear confident in long term growth rates.
- The industry is trading at a PE ratio of 50.6x which is higher than its 3-year average PE of 25.6x.
- The industry is trading close to its 3-year average PS ratio of 6.7x.
Past Earnings Growth
- The earnings for companies in the Life Sciences industry have grown 43% per year over the last three years.
- Revenues for these companies have grown 17% per year.
- This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.
Industry Trends
Which industries have driven the changes within the Hong Kong Healthcare industry?
| HK Market | -1.15% | |
| Healthcare | -3.55% | |
| Life Sciences | -0.93% | |
| Clinical Research and Equipment | -0.93% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 2269 WuXi Biologics (Cayman) | HK$33.20 | 0.9% +HK$1.1b | 195.9% | PE29.5x | |
| 2228 XtalPi Holdings | HK$10.31 | 1.4% +HK$562.4m | 21.4% | PS55.6x | |
| 1873 Viva Biotech Holdings | HK$2.66 | 7.3% +HK$379.6m | 350.8% | PE29.8x | |
| 1521 Frontage Holdings | HK$1.44 | 0.7% +HK$26.1m | 140.0% | PE97.7x | |
| 2576 Zhejiang Taimei Medical Technology | HK$5.01 | 0.2% +HK$5.6m | n/a | PS4.7x |